CN Patent

CN102231953A — 有机化合物

Assigned to Intra Cellular Therapies Inc · Expires 2011-11-02 · 15y expired

What this patent protects

任选被取代的3-(硫基、亚磺酰基或磺酰基)-7，8-二氢-(1H或2H)-咪唑并[1，2-a]吡唑并[4，3-e]嘧啶-4(5H)-酮或被取代的3-(硫基、亚磺酰基或磺酰基)-7，8，9-三氢-(1H或2H)-嘧啶并[1，2-a]吡唑并[4，3-e]嘧啶-4(5H)-酮化合物或式(I)的化合物、它们的制备方法、它们作为药物的用途以及包含它们的药物组合物。

USPTO Abstract

任选被取代的3-(硫基、亚磺酰基或磺酰基)-7，8-二氢-(1H或2H)-咪唑并[1，2-a]吡唑并[4，3-e]嘧啶-4(5H)-酮或被取代的3-(硫基、亚磺酰基或磺酰基)-7，8，9-三氢-(1H或2H)-嘧啶并[1，2-a]吡唑并[4，3-e]嘧啶-4(5H)-酮化合物或式(I)的化合物、它们的制备方法、它们作为药物的用途以及包含它们的药物组合物。

Drugs covered by this patent

Estrace (ESTRADIOL) · Pfizer

Patent Metadata

Patent number: CN102231953A
Jurisdiction: CN
Classification: —
Expires: 2011-11-02
Drug substance claim: No
Drug product claim: No
Assignee: Intra Cellular Therapies Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.